BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 31762217)

  • 1. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
    Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
    Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
    Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
    BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra-Short Course of Neo-Adjuvant Denosumab for Nerve-Sparing Surgery for Giant Cell Tumor of Bone in Sacrum.
    Liang H; Liu X; Yang Y; Guo W; Yang R; Tang X; Yan T; Li Y; Tang S; Li D; Qu H; Dong S; Ji T; Du Z; Zang J
    Spine (Phila Pa 1976); 2022 May; 47(9):691-701. PubMed ID: 34961753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
    Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
    World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
    Sambri A; Medellin MR; Errani C; Campanacci L; Fujiwara T; Donati D; Parry M; Grimer R
    J Orthop Sci; 2020 May; 25(3):513-519. PubMed ID: 31155442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
    Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C
    Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report.
    Tang Q; Lu J; Zhu X; Song G; Wu H; Xu H; Wang A; Wang J
    Eur Spine J; 2023 Dec; 32(12):4297-4305. PubMed ID: 37318598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
    Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
    Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
    Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent giant cell tumour of the distal ulna after en bloc resection with preoperative denosumab use.
    Fujihara N; Hamada S; Yoshida M; Tsukushi S
    BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34764115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
    Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Giant cell tumour of bone in the denosumab era.
    van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
    Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
    J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
    World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
    Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.